PharmaCyte Biotech (PMCB) 10-Q13 Dec 242025 Q2 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	6 Months Ended
Cover - shares	Oct. 31, 2024	Dec. 09, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Oct. 31, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--04-30
Entity File Number	001-40699
Entity Registrant Name	PHARMACYTE BIOTECH, INC.
Entity Central Index Key	0001157075
Entity Tax Identification Number	62-1772151
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3960 Howard Hughes Parkway
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89169
City Area Code	917
Local Phone Number	595-2850
Title of 12(b) Security	Common Stock, Par Value $0.0001 Per Share
Trading Symbol	PMCB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,968,134

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Oct. 31, 2024	Apr. 30, 2024
Current assets:
Cash and cash equivalents	$ 20,840,056	$ 50,179,968
Prepaid expenses and other current assets	493,213	259,800
Total current assets	21,333,269	50,439,768
Other assets:
Intangible asset	1,549,427	1,549,427
Investment in preferred stock – TNF	24,855,000	0
Convertible note receivable – Femasys	3,435,000	2,755,000
Warrant asset – Femasys	3,918,000	5,152,000
Other asset	7,688	7,688
Total other assets	33,765,115	9,464,115
Total Assets	55,098,384	59,903,883
Current liabilities:
Accounts payable	348,595	389,369
Accrued expenses	707,185	735,199
Accrued Series B convertible preferred stock redemption and dividends	3,720,458	6,296,696
Total current liabilities	4,776,238	7,421,264
Other liabilities:
Warrant liability	6,871,000	10,784,000
Derivative liability	0	2,184,000
Total other liabilities	6,871,000	12,968,000
Total Liabilities	11,647,238	20,389,264
Commitments and Contingencies (Notes 6 and 8)
Stockholders' equity:
Preferred stock value	0	0
Common stock: authorized 200,000,000 shares, $0.0001 par value; shares issued 21,672,095, shares outstanding 7,034,259 as of October 31, 2024, and shares issued 21,672,078, shares outstanding 8,037,624 as of April 30, 2024	2,167	2,167
Additional paid-in capital	181,352,842	185,334,173
Accumulated deficit	(93,673,215)	(115,625,010)
Treasury stock, at cost, 14,637,836 and 13,634,454 shares as of October 31, 2024, and April 30, 2024, respectively	(44,207,381)	(42,040,216)
Accumulated other comprehensive loss	(23,267)	(23,511)
Total stockholders' equity	43,451,146	27,647,603
Total Liabilities, Convertible Preferred Stock and Stockholders' Equity	55,098,384	59,903,883
Series B Preferred Stock [Member]
Convertible Preferred Stock:
Convertible preferred stock	0	11,867,016
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Oct. 31, 2024	Apr. 30, 2024
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares authorized	200,000,000	200,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	21,672,095	21,672,078
Common stock, shares outstanding	7,034,259	8,037,624
Treasury stock, common shares	14,637,836	13,634,454
Series B Preferred Stock [Member]
Temporary equity, shares authorized	35,000	35,000
Temporary equity, par value	$ 0.0001	$ 0.0001
Temporary equity, face value	$ 1,000	$ 1,000
Temporary equity, shares issued	0	14,646
Temporary equity, shares outstanding	0	14,646
Shares excluded for redemption	2,979	5,833
Temporary equity, liquidation preference	$ 0	$ 15,060,421
Series A Preferred Stock [Member]
Preferred stock, shares authorized	1	1
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development costs	97,470	82,033	193,486	186,516
Compensation expense	283,333	229,159	672,817	469,157
Director fees	138,000	306,738	276,000	356,953
Legal and professional	469,685	519,073	980,241	844,301
General and administrative	117,572	272,517	252,403	1,627,919
Total operating expenses	1,106,060	1,409,520	2,374,947	3,484,846
Loss from operations	(1,106,060)	(1,409,520)	(2,374,947)	(3,484,846)
Other income (expenses):
Interest income	382,562	894,181	929,994	1,770,059
Change in fair value of warrant liability	1,829,000	4,075,000	3,913,000	2,623,000
Change in fair value of derivative liability	980,000	(769,000)	2,184,000	(1,299,000)
Change in fair value of convertible note receivable	435,000	0	680,000	0
Change in fair value of warrant asset - Femasys	276,000	0	(1,234,000)	0
Change in fair value of investment - TNF	(4,265,000)	0	(3,540,734)	0
Gain on related party investment - TNF	0	0	21,395,734	0
Other expense	(1,062)	(765)	(1,252)	(2,614)
Total other income, net	(363,500)	4,199,416	24,326,742	3,091,445
Net income (loss)	(1,469,560)	2,789,896	21,951,795	(393,401)
Preferred stock dividends	(443,958)	(586,886)	(1,129,759)	(906,735)
Preferred stock accretion	(1,045,357)	(4,461,097)	(3,193,404)	(7,733,130)
Net income (loss) attributable to common stockholders	$ (2,958,875)	$ (2,258,087)	$ 17,628,632	$ (9,033,266)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Income Statement [Abstract]
Earnings Per Share, Basic	$ (0.39)	$ (0.26)	$ 1.83	$ (0.85)
Earnings Per Share, Diluted	$ (0.39)	$ (0.26)	$ 1.83	$ (0.85)
Weighted Average Number of Shares Outstanding, Basic	7,637,034	8,765,134	7,751,708	10,683,514
Weighted Average Number of Shares Outstanding, Diluted	7,637,034	8,765,134	7,751,708	10,683,514

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Income Statement [Abstract]
Net income (loss)	$ (1,469,560)	$ 2,789,896	$ 21,951,795	$ (393,401)
Other comprehensive income (loss):
Foreign currency translation	61	(1,591)	244	(1,140)
Other comprehensive income (loss)	61	(1,591)	244	(1,140)
Comprehensive income (loss)	$ (1,469,499)	$ 2,788,305	$ 21,952,039	$ (394,541)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Apr. 30, 2023	$ 0	$ 2,160	$ 202,230,583	$ (13,560,623)	$ (115,958,773)	$ (23,003)	$ 72,690,344
Beginning balance, shares at Apr. 30, 2023	0	21,602,078		(4,808,098)
Stock issued for warrant exercise		$ 7	63				70
Stock issued for warrant exercise, shares		70,000
Accrued preferred stock dividends			(319,849)				(319,849)
Preferred stock accretion	3,272,033		(3,272,033)				(3,272,033)
Foreign currency translation adjustment						451	451
Net loss					(3,183,297)		(3,183,297)
Repurchase of common stock				$ (26,721,897)			(26,721,897)
Repurchase of common stock, shares				(8,085,879)
Issuance of Series B Preferred Stock, net of discounts and issuance costs of $18,246,925	$ 16,753,075
Issuance of Series B Preferred Stock, net of discounts and issuance costs, shares	35,000
Ending balance, value at Jul. 31, 2023	$ 20,025,108	$ 2,167	198,638,764	$ (40,282,520)	(119,142,070)	(22,552)	39,193,789
Ending balance, shares at Jul. 31, 2023	35,000	21,672,078		(12,893,977)
Beginning balance, value at Apr. 30, 2023	$ 0	$ 2,160	202,230,583	$ (13,560,623)	(115,958,773)	(23,003)	72,690,344
Beginning balance, shares at Apr. 30, 2023	0	21,602,078		(4,808,098)
Net loss							(393,401)
Ending balance, value at Oct. 31, 2023	$ 21,297,669	$ 2,167	193,590,781	$ (40,449,123)	(116,352,174)	(24,143)	36,767,508
Ending balance, shares at Oct. 31, 2023	31,480	21,672,078		(12,972,086)
Beginning balance, value at Jul. 31, 2023	$ 20,025,108	$ 2,167	198,638,764	$ (40,282,520)	(119,142,070)	(22,552)	39,193,789
Beginning balance, shares at Jul. 31, 2023	35,000	21,672,078		(12,893,977)
Series B preferred stock subject to redemption	$ (3,188,536)
Series B preferred stock subject to redemption, shares	(3,520)
Series B preferred stock dividends			(586,886)				(586,886)
Preferred stock accretion	4,461,097		(4,461,097)				(4,461,097)
Repurchase of common stock				$ (166,603)			(166,603)
Repurchase of common stock, shares				(78,109)
Foreign currency translation adjustment						(1,591)	(1,591)
Net loss					2,789,896		2,789,896
Ending balance, value at Oct. 31, 2023	$ 21,297,669	$ 2,167	193,590,781	$ (40,449,123)	(116,352,174)	(24,143)	36,767,508
Ending balance, shares at Oct. 31, 2023	31,480	21,672,078		(12,972,086)
Beginning balance, value at Apr. 30, 2024	$ 11,867,016	$ 2,167	185,334,173	$ (42,040,216)	(115,625,010)	(23,511)	27,647,603
Beginning balance, shares at Apr. 30, 2024	14,646	21,672,078		(13,634,454)
Stock-based compensation options			222,677				222,677
Preferred stock accretion	2,148,047		(2,148,047)				(2,148,047)
Series B preferred stock redemption	$ (2,893,144)
Series B preferred stock redemption, shares	(2,917)
Series B preferred stock subject to redemption	$ (5,788,805)
Series B preferred stock subject to redemption, shares	(5,833)
Preferred stock dividends			(685,801)				(685,801)
Foreign currency translation adjustment						183	183
Net loss					23,421,355		23,421,355
Repurchase of common stock				$ (749,600)			(749,600)
Repurchase of common stock, shares				(320,346)
Ending balance, value at Jul. 31, 2024	$ 5,333,114	$ 2,167	182,723,002	$ (42,789,816)	(92,203,655)	(23,328)	47,708,370
Ending balance, shares at Jul. 31, 2024	5,896	21,672,078		(13,954,800)
Beginning balance, value at Apr. 30, 2024	$ 11,867,016	$ 2,167	185,334,173	$ (42,040,216)	(115,625,010)	(23,511)	27,647,603
Beginning balance, shares at Apr. 30, 2024	14,646	21,672,078		(13,634,454)
Net loss							21,951,795
Ending balance, value at Oct. 31, 2024	$ 0	$ 2,167	181,352,842	$ (44,207,381)	(93,673,215)	(23,267)	43,451,146
Ending balance, shares at Oct. 31, 2024	0	21,672,095		(14,637,836)
Beginning balance, value at Jul. 31, 2024	$ 5,333,114	$ 2,167	182,723,002	$ (42,789,816)	(92,203,655)	(23,328)	47,708,370
Beginning balance, shares at Jul. 31, 2024	5,896	21,672,078		(13,954,800)
Fractional shares adjustment
Fractional shares adjustment, shares		17
Stock-based compensation options			119,155				119,155
Preferred stock accretion	1,045,357		(1,045,357)				(1,045,357)
Series B preferred stock redemption	$ (2,868,607)
Series B preferred stock redemption, shares	(2,917)
Series B preferred stock subject to redemption	$ (3,509,864)
Series B preferred stock subject to redemption, shares	(2,979)
Preferred stock dividends			(443,958)				(443,958)
Foreign currency translation adjustment						61	61
Net loss					(1,469,560)		(1,469,560)
Repurchase of common stock				$ (1,417,565)			(1,417,565)
Repurchase of common stock, shares				(683,036)
Ending balance, value at Oct. 31, 2024	$ 0	$ 2,167	$ 181,352,842	$ (44,207,381)	$ (93,673,215)	$ (23,267)	$ 43,451,146
Ending balance, shares at Oct. 31, 2024	0	21,672,095		(14,637,836)

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical)	3 Months Ended
	Jul. 31, 2023 USD ($)
Preferred Stock [Member]
Net of discounts and issuance costs	$ 18,246,925

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Cash flows from operating activities:
Net income (loss)	$ 21,951,795	$ (393,401)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on related party investment – TNF	(21,395,734)	0
Stock-based compensation	341,832	0
Change in fair value of warrant liability	(3,913,000)	(2,623,000)
Change in fair value of derivative liability	(2,184,000)	1,299,000
Change in fair value of convertible note receivable	(680,000)	0
Change in fair value of warrant asset – Femasys	1,234,000	0
Change in fair value of investment – TNF	3,540,734	0
Change in assets and liabilities:
Decrease in prepaid expenses and other current assets	(233,413)	(215,508)
Increase (decrease) in accounts payable	(40,775)	(2,118)
Increase (decrease) in accrued expenses	(49,471)	293,632
Net cash provided by (used in) operating activities	(1,428,032)	(1,641,395)
Cash flows from investing activities:
Investment in preferred stock and warrants	(7,000,000)	0
Net cash used in investing activities	(7,000,000)	0
Cash flows from financing activities:
Repurchase of common stock	(2,145,708)	(26,622,277)
Proceeds from issuance of preferred stock	0	33,650,075
Redemption of preferred stock	(18,766,416)	0
Proceeds from warrant exercise	0	70
Net cash provided by (used in) financing activities	(20,912,124)	7,027,868
Effect of currency rate exchange on cash and cash equivalents	244	(1,140)
Net increase (decrease) in cash and cash equivalents	(29,339,912)	5,385,333
Cash and cash equivalents at beginning of the period	50,179,968	68,039,936
Cash and cash equivalents at end of the period	20,840,056	73,425,269
Supplemental disclosure of cash flows information:
Cash paid during the periods for income taxes	0	1,600
Supplemental disclosure of cash flows information:
Non-cash derivative liability at initial fair value	0	2,770,000
Non-cash warrant liability at initial fair value	0	14,127,000
Reclassification of Series B Convertible Preferred Stock and dividends to current liability	16,190,179	4,095,271
Accretion of discounts to redemption value of Series B Preferred Stock	3,193,404	7,733,130
Excise tax accrued on repurchase of common stock	$ 21,457	$ 266,223

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended				6 Months Ended
Pay vs Performance Disclosure - USD ($)	Oct. 31, 2024	Jul. 31, 2024	Oct. 31, 2023	Jul. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (1,469,560)	$ 23,421,355	$ 2,789,896	$ (3,183,297)	$ 21,951,795	$ (393,401)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Oct. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

NATURE OF BUSINESS

NATURE OF BUSINESS	6 Months Ended
NATURE OF BUSINESS	Oct. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS	NOTE 1 – NATURE OF BUSINESS PharmaCyte Biotech, Inc. (“Company”) is a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box ® ® The Company is a Nevada corporation incorporated in 1996. In 2013, the Company restructured its operations to focus on biotechnology. The Company acquired licenses from SG Austria Pte. Ltd., a Singapore corporation (“SG Austria”) to treat cancer and Austrianova Singapore Pte. Ltd., a Singapore corporation (“Austrianova Singapore”) using the Cell-in-the-Box technology. The restructuring resulted in the Company focusing all its efforts upon the development of a novel, effective and safe way to treat cancer. In January 2015, the Company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to reflect the nature of its current business. In October 2021, the Company moved its headquarters from Laguna Hills, California to Las Vegas, Nevada. On September 1, 2020, the Company submitted an Investigational New Drug Application (“IND”) to the U.S. Food and Drug Administration (“FDA”) for a planned clinical trial in LAPC. On October 1, 2020, the Company received notice from the FDA that it had placed the IND on clinical hold. On October 30, 2020, the FDA sent a letter to the Company setting forth the reasons for the clinical hold and specific guidance on what the Company must do to have the clinical hold lifted. To lift the clinical hold, the FDA informed the Company that it needs to conduct several additional preclinical studies. The FDA also requested additional information regarding several topics, including DNA sequencing data, manufacturing information and product release specifications. The Company has been in the process of conducting these studies and gathering additional information to submit to the FDA. See “Investigational New Drug Application and Clinical Hold” below. On August 15, 2022, the Company entered into a Cooperation Agreement (“Cooperation Agreement”) with Iroquois Master Fund Ltd. and its affiliates, pursuant to which the Company elected a reconstituted Board of Directors (”Board”). The Board has formed a Business Review Committee to evaluate, investigate and review the Company’s business, affairs, strategy, management and operations and in its sole discretion to make recommendations to the Company’s management and Board with respect thereto. The Business Review Committee is also reviewing many of the risks relative to the Company’s business. In addition, the Board is reviewing the Company’s development programs and its relationship with SG Austria, including that all licensed patents have expired, that know-how relating to the Company’s Cell-in-a-Box® technology solely resides with SG Austria, and that the incentives of SG Austria and its management may not be currently aligned with those of the Company. The Board has curtailed spending on the Company’s programs, including pre-clinical and clinical activities, until the review by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented. The Business Review Committee’s recommendations will include potentially seeking a new framework for the Company’s relationship with SG Austria and its subsidiaries. In the event the Company is unsuccessful in seeking an acceptable new framework, the Company will reevaluate whether it should continue those programs which are dependent on SG Austria, including its development programs for LAPC. The issues involving SG Austria have delayed the Company’s timeline for addressing the FDA clinical hold for its planned clinical trial in LAPC and could result in other delays or termination of the development activities. In addition, the curtailment of spending on the Company’s programs pending the review by the Business Review Committee and the Board may cause additional delays. The Cell-in-a-Box ® The Company has been developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells that it believes are capable of converting a cancer prodrug into its cancer-killing form. The Company encapsulates those cells using the Cell-in-a-Box ® Until the review by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented, spending on the Company’s programs has been curtailed. Investigational New Drug Application and Clinical Hold On September 1, 2020, the Company submitted an IND to the FDA for a planned clinical trial in LAPC. On October 1, 2020, the Company received notice from the FDA that it had placed the Company’s IND on clinical hold. On October 30, 2020, the FDA sent the Company a letter setting forth the reasons for the clinical hold and providing specific guidance on what the Company must do to have the clinical hold lifted. In order to address the clinical hold, the FDA requested that the Company: · Provide additional sequencing data and genetic stability studies; · Conduct a stability study on ‌the Company’s final formulated product candidate as well as the cells from the Company’s Master Cell Bank; · Evaluate the compatibility of the delivery devices (the prefilled syringe and the microcatheter used to implant the CypCaps ™ · Provide additional detailed description of the manufacturing process of ‌the Company’s product candidate for pancreatic cancer; · Provide additional product release specifications for the Company’s encapsulated cells; · Demonstrate comparability between the 1 st nd · Conduct a biocompatibility assessment using the Company’s capsules material; · Address specified insufficiencies in the Chemistry, Manufacturing and Controls information in the cross-referenced Drug Master File; · Conduct an additional nonclinical study in a large animal (such as a pig) to assess the safety, activity, and distribution of the product candidate for pancreatic cancer; and · Revise the Investigators Brochure to include any additional preclinical studies conducted in response to the clinical hold and remove any statements not supported by the data the Company generated. The FDA also requested that the Company address the following issues as an amendment to the Company’s IND: · Provide a Certificate of Analysis for pc3/2B1 plasmid that includes tests for assessing purity, safety, and potency; · Perform qualification studies for the drug filling step to ensure that the Company’s product candidate for pancreatic cancer remains sterile and stable during the filling process; · Submit an updated batch analysis for the Company’s product candidate for the specific lot that will be used for manufacturing all future product candidates; · Provide additional details for the methodology for the Resorufin (CYP2B1) potency and the PrestoBlue cell metabolic assays; · Provide a few examples of common microcatheters that fit the specifications in ‌the Company’s Angiography Procedure Manual; · Clarify the language in ‌our Pharmacy Manual regarding proper use of the syringe fill with the Company’s product candidate for pancreatic cancer; and · Provide a discussion with data for trial of the potential for cellular and humoral immune reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in ‌our study population. The Company assembled a scientific and regulatory team of experts to address the FDA requests. That team has been working diligently to complete the items requested by the FDA.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Oct. 31, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of October 31, 2024 and for the three and six months then ended. The results of operations for the three and six months ended October 31, 2024 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of April 30, 2024 and for the year then ended which are included in the Company’s Annual Report on Form 10- K, filed with the SEC on August 13, 2024. Liquidity Uncertainties As of October 31, 2024, the Company had approximately $ 20.8 50.2 The Company may need to raise additional capital in order to initiate and pursue potential additional projects, including the continuing development beyond the ongoing pancreatic cancer research. Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders, and debt financing, if available, may have restrictive covenants. If the Company is able to find funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its product candidates that the Company would otherwise seek to develop on its own, on terms that may not be favorable to the Company. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on the business, financial condition and results of operations. Basic and Diluted Income (Loss) Per Share Basic earnings per share excludes dilution for common stock equivalents and is computed by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted EPS is calculated based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period. Potentially dilutive securities consist of common stock options, warrants, and convertible preferred securities. The dilutive effect of stock options and warrants is reflected in diluted EPS by application of the treasury stock method. The dilutive effect of convertible preferred securities is reflected in the diluted EPS by application of the “if-converted” method. The “if-converted” method is only assumed in periods where such application would be dilutive. Basic and diluted net income (loss) per share is determined by dividing income (loss) by the weighted average ordinary shares outstanding during the period. For periods presented with a net loss, the shares underlying the ordinary share options, warrants and preferred stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per share is the same for periods with a net loss. Investment in TNF Pharmaceuticals, Inc. In accordance with ASC 810, Consolidation If an entity is determined to be a VIE, the Company evaluates whether it is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. PharmaCyte consolidates a VIE if it has both power and benefits that is, PharmaCyte (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). PharmaCyte consolidates VIEs whenever it is determined that PharmaCyte is the primary beneficiary. The Company applies ASC 321 Investments—Equity Securities New Accounting Pronouncements Effective in Future Periods In November 2023, FASB issued ASU 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities with a single reportable segment to provide all the disclosures required by this standard and all existing segment disclosures in Topic 280 on an interim and annual basis, including new requirements to disclose significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within the reported measure(s) of a segment's profit or loss, the amount and composition of any other segment items, the title and position of the CODM, and how the CODM uses the reported measure(s) of a segment's profit or loss to assess performance and decide how to allocate resources. The guidance is effective for our annual period beginning May 1, 2025, and interim periods, thereafter, applied retrospectively with early adoption permitted. The Company is evaluating the impact of adoption of this standard on its financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to provide greater disaggregation within their annual rate reconciliation, including new requirements to present reconciling items on a gross basis in specified categories, disclose both percentages and dollar amounts, and disaggregate individual reconciling items by jurisdiction and nature when the effect of the items meet a quantitative threshold. The guidance also requires disaggregating the annual disclosure of income taxes paid, net of refunds received, by federal (national), state, and foreign taxes, with separate presentation of individual jurisdictions that meet a quantitative threshold. The guidance is effective for the Company's annual periods beginning May 1, 2025 on a prospective basis, with a retrospective option, and early adoption is permitted. The Company is evaluating the impact of adoption of this standard on its financial statements and disclosures.

INVESTMENT IN FEMASYS SECURITIE

INVESTMENT IN FEMASYS SECURITIES	6 Months Ended
INVESTMENT IN FEMASYS SECURITIES	Oct. 31, 2024
Investments, Debt and Equity Securities [Abstract]
INVESTMENT IN FEMASYS SECURITIES	NOTE 3 – INVESTMENT IN FEMASYS SECURITIES On November 14, 2023, the Company entered into a Securities Purchase Agreement (the “Femasys Purchase Agreement”) with Femasys Inc. (“Femasys”), pursuant to which it agreed to purchase from Femasys for a sum of $5,000,000, (i) senior unsecured convertible notes (the “Femasys Notes”) in an aggregate principal amount of $ 5,000,000 1.18 4,237,288 Pursuant to the terms of the Femasys Purchase Agreement, the Company’s Interim Chief Executive Officer was appointed to the Femasys board of directors. The convertible note receivable is not traded in active markets and the fair value was determined using a Monte Carlo simulation. The convertible note receivable is accounted for as available-for-sale debt securities based on “Level 3” inputs, which consist of unobservable inputs and reflect management’s estimates of assumptions that market participants would use in pricing the asset. The Company elected the fair value option for the Femasys Notes, therefore, holding gains and losses are included within change in fair value of the notes in the condensed consolidated statement of operations. The Femasys Warrants are accounted for as an equity security and are valued using a Monte Carlo simulation based on “Level 3” inputs, which consist of unobservable inputs and reflect management’s estimates of assumptions that market participants would use in pricing the asset, recorded at fair value with subsequent changes included within change in fair value of the warrants in the condensed consolidated statement of operations. The Company recognized the Femasys Note and Femasys Warrants based on their respective fair values on the issuance date of $ 1,666,000 3,334,000 435,000 680,000 276,000 1,234,000 Below is a summary of activity for the Note and Warrants as of October 31, 2024: Schedule of activity for the notes and warrants Balance of Notes as of May 1, 2024 $ 2,755,000 Purchased – Change in fair value 680,000 Balance of Notes as of October 31, 2024 $ 3,435,000 Balance of Warrants as of May 1, 2024 $ 5,152,000 Purchased – Change in fair value (1,234,000 ) Balance of Warrants as of October 31, 2024 $ 3,918,000

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
ACCRUED EXPENSES	Oct. 31, 2024
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 4 – ACCRUED EXPENSES Accrued expenses at October 31, 2024 and April 30, 2024, are summarized below: Schedule of accrued expenses October 31, 2024 April 30, 2024 Payroll related costs $ 185,846 $ 167,817 Director fees 67,500 135,000 R&D costs 92,310 92,310 Excise tax on stock repurchases 361,529 340,072 Total $ 707,185 $ 735,199

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	6 Months Ended
STOCK OPTIONS AND WARRANTS	Oct. 31, 2024
Share-Based Payment Arrangement [Abstract]
STOCK OPTIONS AND WARRANTS	NOTE 5 – STOCK OPTIONS AND WARRANTS 2022 Equity Incentive Plan Effective December 28, 2022, the Company implemented the 2022 Equity Incentive Plan (“2022 Equity Plan”) as approved by the Company’s stockholders. The 2022 Equity Plan is administered by the Compensation Committee of the Board and has 2,750,000 Stock Options As of October 31, 2024, the Company had 923,698 During the six months ended October 31, 2024, and 2023, the Company granted no During the six months ended October 31, 2024 and 2023, the Company granted no A summary of the Company’s stock option activity and related information for the six months ended October 31, 2024, are shown below: Schedule of stock option activity and related information Options Number of Options Weighted Average Exercise Price per Share Outstanding, April 30, 2024 925,164 $ 2.97 Issued – – Expired (1,466 ) 55.30 Outstanding, October 31, 2024 923,698 $ 2.89 Exercisable, October 31, 2024 644,161 $ 3.21 Vested and expected to vest 923,698 $ 2.89 A summary of the activity for unvested stock options during the six months ended October 31, 2024 is as follows: Schedule of unvested stock option activity Options Weighted Unvested, April 30, 2024 279,536 1.70 Granted – – Vested – – Forfeited – – Unvested, October 31, 2024 279,536 $ 1.70 The Company recorded $ 119,155 341,833 0 0 132,859 The aggregate intrinsic value of outstanding options as of October 31, 2024 was $ 0 Warrants Pursuant to the Private Placement (as defined below), the Company issued investors Warrants (as defined below) to purchase 8,750,000 4.00 The Warrants were determined to be within the scope of ASC 480-10 as they are puttable to the Company at Holders’ election upon the occurrence of a Fundamental Transaction (as defined in the agreements). As such, the Company recorded the Warrants as a liability at fair value with subsequent changes in fair value recognized in earnings. The Company utilized the Black-Scholes-Merton Model to calculate the value of the Warrants issued on May 10, 2023. The fair value of the Warrants of approximately $ 14,127,000 Transaction costs incurred attributable to the issuance of the Warrants of approximately $ 913,640 During the three and six months ended October 31, 2024, the Company recorded a gain of approximately $ 1,829,000 3,913,000 6,871,000 A summary of the Company’s warrant activity and related information for the six months ended October 31, 2024, are shown below: Schedule of warrant activity and related information Warrants Weighted Per Share Outstanding, April 30, 2024 18,570,847 $ 4.54 Issued – – Exercised – – Expired – – Outstanding, October 31, 2024 18,570,847 4.54 Exercisable, October 31, 2024 18,570,847 $ 4.54

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS	6 Months Ended
LEGAL PROCEEDINGS	Oct. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
LEGAL PROCEEDINGS	NOTE 6 – LEGAL PROCEEDINGS From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on our financial condition or operating results. On December 4, 2023, H.C. Wainwright & Co., LLC (“Wainwright”) filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, asserting a single cause of action for breach of contract and alleging that the Company breached an April 2021 engagement agreement with Wainwright by failing to pay a purported “tail fee” allegedly due in connection with a private placement transaction that closed in 2023. Wainwright seeks damages of not less than $1,950,000, warrants to purchase an aggregate of 656,250 shares of our common stock at an exercise price of $5.00 per share, and attorney’s fees. On February 28, 2024, the Company responded to the complaint with an answer and affirmative defenses. The parties have commenced documentary discovery. The Company intends to vigorously defend against Wainwright’s complaint and does not believe that any potential loss is reasonably probable at this time. To our knowledge there are no other legal proceedings pending to which any property of the Company is subject.

OTHER RELATED PARTY TRANSACTION

OTHER RELATED PARTY TRANSACTIONS	6 Months Ended
OTHER RELATED PARTY TRANSACTIONS	Oct. 31, 2024
Related Party Transactions [Abstract]
OTHER RELATED PARTY TRANSACTIONS	NOTE 7 – OTHER RELATED PARTY TRANSACTIONS The Company had the following related party transactions during the three and six months ended October 31, 2024 and 2023, respectively. The Company owns 13.9 ASC 321 - Investments Equity Securities 0 In April 2014, the Company entered the Vin-de-Bona Consulting Agreement pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona is owned by Prof. Günzburg and Dr. Salmons, both of whom are involved in numerous aspects of the Company’s scientific endeavors relating to cancer (Prof. Günzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and President of Austrianova). The term of the agreement is for 12 months and is automatically renewable for successive 12-month terms. After the initial term, either party can terminate the agreement by giving the other party 30 days’ written notice before the effective date of termination. To date, the agreement has been automatically renewed annually. The amounts incurred for the three and six months ended October 31, 2024, were approximately $ 2,670 5,280 2,590 2,700 The Company’s Interim Chief Executive Officer was appointed to the Femasys board of directors, see Note 3. The Company’s Interim Chief Executive Officer serves on the board of directors of TNF, see Note 13.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Oct. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES The Company acquires assets still in development and enters research and development (“R&D”) arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based upon a percentage of the sales of the pharmaceutical products if regulatory approval for marketing is obtained. Office Lease In January 2023, the Company entered into a month-to-month agreement of the Las Vegas office space, commencing on May 1, 2023. Additionally, the Company rents storage space pursuant to a month-to-month agreement in Laguna Hills, California. Rent expenses for these offices for the three and six months ended October 31, 2024 were $ 7,071 14,281 6,631 15,598 With the month-to-month office rental agreements there are no aggregate future minimum lease payments required to be made. Service Agreements The Company has entered into several service agreements with independent and related parties pursuant to which services will be provided over a specified period-of-time related to the IND which the FDA has placed on clinical hold. The services include regulatory affairs strategy, advice and follow up work on the IND and services related to having the clinical hold lifted. The total cost is estimated to be approximately $212,000, of which the related party (SG Austria and its subsidiaries) portion will be approximately $157,000. These amounts take into account some of the costs associated with the work and preclinical studies required to lift the clinical hold.

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
EARNINGS PER SHARE	Oct. 31, 2024
Earnings Per Share [Abstract]
EARNINGS PER SHARE	NOTE 9 – EARNINGS PER SHARE The Company computes earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation formula that determines earnings per share for common stock and any participating securities according to dividends declared (whether paid or unpaid) and participation rights in undistributed earnings. The Series B Preferred Shares are considered participating securities as preferred shareholders are entitled to participate with common stockholders on an as-converted basis in any distributions of assets by the Company under the terms of the Certificate of Designations. Under the two-class method, there is no change in the weighted average shares outstanding used between the basic and diluted earnings per share calculations as the Series B Preferred Shares represent the only dilutive share equivalents during the three and six months ended October 31, 2024 and 2023. During the three months ended October 31, 2024 and 2023, and the six months ended October 31, 2023, the Company incurred losses attributable to common shareholders. Accordingly, the effects of any common stock equivalent would be anti-dilutive during the period and thus are not included in the calculation of diluted weighted average number of shares outstanding. The following table illustrates the computation of basic and diluted earnings (loss) per share: Schedule of basic and diluted earnings (loss) per share Three Months Ended October 31, 2024 2023 Earnings per share Net income (loss) $ (1,469,560 ) $ 2,789,896 Less: Accretion of discounts to redemption of Series B convertible preferred stock (443,958 ) (586,886 ) Less: Series B convertible preferred stock dividends (1,045,357 ) (4,461,097 ) Less: Allocation of undistributed income to Series B convertible preferred stock – – Net loss attributable to common stockholders $ (2,958,875 ) $ (2,258,087 ) Weighted average shares outstanding used in basic and diluted earnings per share 7,637,034 8,765,134 Net loss per share basic and diluted $ (0.39 ) $ (0.26 ) Six Months Ended October 31, 2024 2023 Earnings per share Net income (loss) $ 21,951,795 $ (393,401 ) Less: Accretion of discounts to redemption of Series B convertible preferred stock (3,193,404 ) (7,733,130 ) Less: Series B convertible preferred stock dividends (1,129,759 ) (906,735 ) Less: Allocation of undistributed income to Series B convertible preferred stock (3,409,913 ) – Undistributed income (loss) available to common stockholders $ 14,218,719 $ (9,033,266 ) Weighted average shares outstanding used in basic earnings per share 7,751,708 10,683,514 Net income (loss) per share basic and diluted $ 1.83 $ (0.85 ) The table below sets forth the potentially dilutive securities excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: Schedule of potentially dilutive securities Three and Six Months Ended 2024 2023 Excluded options 923,696 279,802 Excluded warrants 18,570,847 18,570,847 Total excluded options and warrants 19,494,543 18,850,649

PREFERRED STOCK

PREFERRED STOCK	6 Months Ended
PREFERRED STOCK	Oct. 31, 2024
Equity [Abstract]
PREFERRED STOCK	NOTE 10 – PREFERRED STOCK The Company has authorized 10,000,000 0.0001 35,000 0 14,646 0 11,867,016 On May 10, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors (i) an aggregate of 35,000 shares of the Company’s newly-designated Series B convertible preferred stock with a stated value of $1,000 per share, initially convertible into up to 8,750,000 shares of the Company’s common stock, par value $0.0001 per share at a conversion price of $4.00 per share (the “Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 8,750,000 shares of common stock (the “Warrants”) (collectively, the “Private Placement”). The terms of the Preferred Shares are as set forth in a Certificate of Designations (the “Certificate of Designations”), which was filed with the Secretary of the State of Nevada on May 10, 2023. The Preferred Shares are convertible into common stock (the “Conversion Shares”) at the election of the holder at any time at an initial conversion price of $4.00 (the “Conversion Price”). The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of common stock, or securities convertible, exercisable or exchangeable for common stock, at a price below the then-applicable Conversion Price (subject to certain exceptions). The Company is required to settle the Preferred Shares in equal monthly installments, commencing on November 9, 2023. The amortization payments due upon such redemption are payable, at the Company’s election, in cash, or subject to certain limitations, in shares of common stock valued at the lower of (i) the Conversion Price then in effect and (ii) the greater of (A) a 20% discount to the average of the three lowest closing prices of the Company’s common stock during the thirty trading day period immediately prior to the date the amortization payment is due or (B) the lower of $0.556 and 20% of the Minimum Price (as defined in Rule 5635 of the Rule of the Nasdaq Stock Market) on the date of receipt of Nasdaq Stockholder Approval (as defined below); provided that if the amount set forth in clause B is the lowest effective price, the Company will be required to pay the amortization payment in cash. The Company may require holders to convert their Preferred Shares into Conversion Shares if the closing price of the common stock exceeds $6.00 per share for 20 consecutive trading days and the daily trading volume of the common stock exceeds 1,000,000 shares per day during the same period and certain equity conditions described in the Certificate of Designations are satisfied. The holders of the Preferred Shares are entitled to dividends of 4% per annum, compounded monthly, which are payable in cash or shares of common stock at the Company’s option, in accordance with the terms of the Certificate of Designations. Upon the occurrence and during the continuance of a Triggering Event (as defined in the Certificate of Designations), the Preferred Shares will accrue dividends at the rate of 15% per annum. The holders of Preferred Shares have no voting rights on account of the Preferred Shares, other than with respect to certain matters affecting the rights of the Preferred Shares. Notwithstanding the foregoing, the Company’s ability to settle conversions and make amortization payments using shares of common stock is subject to certain limitations set forth in the Certificate of Designations, including a limit on the number of shares that may be issued until the time, if any, that the Company’s stockholders have approved the issuance of more than 19.9% of the Company’s outstanding shares of common stock in accordance with Nasdaq listing standards (the “Nasdaq Stockholder Approval”). The Company received Nasdaq Stockholder Approval at its special meeting of stockholders held on August 31, 2023. Further, the Certificate of Designations contains a certain beneficial ownership limitation after giving effect to the issuance of shares of common stock issuable upon conversion of, or as part of any amortization payment under, the Certificate of Designations or Warrants. The Certificate of Designations includes certain Triggering Events (as defined in the Certificate of Designations), including, among other things, the failure to file and maintain an effective registration statement covering the sale of the holder’s securities registrable pursuant to a registration rights agreement entered into by the Company and the Investors simultaneously with the Purchase Agreement and the Company’s failure to pay any amounts due to the holders of the Preferred Shares when due. In connection with a Triggering Event, each holder of Preferred Shares will be able to require the Company to redeem in cash any or all of the holder’s Preferred Shares at a premium set forth in the Certificate of Designations. The Preferred Shares were determined to be more akin to a debt-like host than an equity-like host. The Company identified the following embedded features that are not clearly and closely related to the debt host instrument: 1) an installment redemption upon an Equity Conditions Failure (as defined in the Certificate of Designation), and 2) variable share-settled installment conversion. These features were bundled together, assigned probabilities of being affected and measured at fair value. Subsequent changes in the fair value of these features are recognized in the Condensed Consolidated Statements of Operations. The Company estimated the $2,770,000 fair value of the bifurcated embedded derivative at issuance using a Monte Carlo simulation model, with the following inputs: the fair value of the Company’s common stock of $2.74 on the issuance date, estimated equity volatility of 55.0%, estimated traded volume volatility of 355.0%, the time to maturity of 1.50 years, a discounted market interest rate of 15.9%, a risk free rate of 4.3%, dividend rate of 4.0%, a penalty dividend rate of 15.0%, and probability of default of 27.0%. The fair value of the bifurcated derivative liability was estimated utilizing the with and without method which uses the probability weighted difference between the scenarios with the derivative and the plain vanilla maturity scenario without a derivative. During the three and six months ended October 31, 2024, the Company recorded a gain of approximately $ 980,000 2,184,000 0 no During the three and six months ended October 31, 2024, the Company made all installment payments in cash pursuant to installment redemptions. The installment redemptions were paid in cash in the amounts of $ 9,336,833 18,766,416 8,750,000 17,500,000 58,333 204,166 528,500 1,062,250 1,045,357 3,193,404 528,500 1,062,250 As of October 31, 2024, the Company has reclassified a portion of the Preferred Shares to an accrued liability for the final (thirteenth) installment redemptions owed to investors in cash of $ 3,720,458 2,979,167 530,698 210,593 The Company has one share of preferred stock designated as “Series A Preferred Stock” as of October 31, 2024 and April 30, 2024, there were no shares of Series A Preferred Stock issued and outstanding. The description of the Series A Preferred Stock below is qualified in its entirety by reference to the Company’s Articles of Incorporation, as amended. The Series A Preferred Stock has the following features: · There is one share of preferred stock designated as Series A Preferred Stock; · The Series A Preferred Stock has a number of votes at any time equal to the number of votes then held by all other shareholders of the Company having a right to vote on any matter plus one. The Certificate of Designations that designated the terms of the Series A Preferred Stock cannot be amended without the consent of the holder of the Series A Preferred Stock; · The Company may redeem the Series A Preferred Stock at any time for a redemption price of $1.00 paid to the holder of the share of Series A Preferred Stock; and · The Series A Preferred Stock has no rights of transfer, conversion, dividends, preferences upon liquidation or participation in any distributions to shareholders.

TREASURY STOCK

TREASURY STOCK	6 Months Ended
TREASURY STOCK	Oct. 31, 2024
Equity [Abstract]
TREASURY STOCK	NOTE 11 – TREASURY STOCK In May 2022, the Board authorized a share repurchase program to acquire its outstanding common stock for up to $ 10 683,036 1,003,382 1,417,565 2,167,165 6,551,957 17,485,484 2,514,516 Tender Offer On May 11, 2023, the Company commenced a tender offer, in accordance with Rule 13e-4 promulgated under the Securities Exchange Act of 1934, as amended, to purchase up to 7,750,000 shares of its common stock, par value $0.0001 per share, at a price of $3.25 per share. The tender offer expired one minute after 11:59 p.m. on June 9, 2023, and following such expiration the Company accepted for purchase a total of 8,085,879 26,721,897 As of October 31, 2024, the total number of shares held in Treasury Stock is 14,637,836 44,207,381

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
FAIR VALUE MEASUREMENTS	Oct. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 12 – FAIR VALUE MEASUREMENTS Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the six months ended October 31, 2024. The carrying amounts of cash equivalents, other current assets, accounts payable and accrued expenses approximate their face values at October 31, 2024 due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible preferred stock was estimated using a Monte Carlo simulation model, which uses as inputs the fair value of the Company’s common stock and estimates for the equity volatility and traded volume volatility of the Company’s common stock, the time maturity of the convertible preferred stock, the risk-free interest rate for a period of time that approximates the time to maturity, dividend rate, a penalty dividend rate and the probability of default. The fair value of the warrant liability was estimated using the Black Scholes Merton Model which uses as inputs the following weighted average assumptions, as noted above: dividend yield, expected terms in years, equity volatility and risk-free rate. Fair Value on a Recurring Basis The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported and reported at fair at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the warrant liability and bifurcated embedded derivative represent Level 3 measurements. The bifurcated embedded derivative was extinguished as a result of the redemption of the Series B convertible notes. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at October 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of fair value of financial liabilities Description Level October 31, 2024 April 30, 2024 Liabilities: Warrant liability 3 $ 6,871,000 $ 10,784,000 Bifurcated embedded derivative 3 $ – $ 2,184,000 The following table sets forth a summary of the change in the fair value of the warrant liability that is measured at fair value on a recurring basis. Schedule of change in the fair value of the warrant liability Three Months Ended October 31, 2024 Balance on July 31, 2024 $ 8,700,000 Issuance of warrants – Change in fair value of warrant liability (1,829,000 ) Balance on October 31, 2024 $ 6,871,000 Six Months Ended October 31, 2024 Balance on April 30, 2024 $ 10,784,000 Issuance of warrants – Change in fair value of warrant liability (3,913,000 ) Balance on October 31, 2024 $ 6,871,000 The following table sets forth a summary of the change in the fair value of the bifurcated embedded derivative liability that is measured on a recurring basis: Schedule of embedded derivative liability Three Months Ended October 31, 2024 Balance on July 31, 2024 $ 980,000 Issuance of convertible preferred stock with bifurcated embedded derivative liability – Change in fair value of bifurcated embedded derivative (980,000 ) Balance on October 31, 2024 $ – Six Months Ended October 31, 2024 Balance on April 30, 2024 $ 2,184,000 Issuance of convertible preferred stock with bifurcated embedded derivative liability – Change in fair value of bifurcated embedded derivative (2,184,000 ) Balance on October 31, 2024 $ – The fair value of the convertible note receivable using the income approach, which uses as inputs the fair value of debtor’s common stock and estimates for the equity volatility and volume volatility of debtor’s common stock, the time to expiration of the convertible note, the discount rate, the stated interest rate compared to the current market rate, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the estimate of expected future volatility is based on the actual volatility of debtor’s common stock and historical volatility of debtor’s common stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default is estimated using the S&P Global default rate for companies with a similar credit rating to debtor’s. The fair values of financial instruments by class as of October 31, 2024 are as follows: Schedule of fair values of financial instruments by class Level October 31, 2024 April 30, 2024 Financial Assets Convertible note receivable – investment in debt security 3 $ 3,435,000 $ 2,755,000 Warrant asset – Femasys 3 $ 3,918,000 $ 5,152,000 Investment in preferred stock - TNF 3 $ 18,799,000 $ – Warrant asset – TNF 3 $ 6,056,000 $ – Assumptions used in the valuation of the Level 3 assets include time to expiration, discount rate, risk-free rate, volatility and probability of default.

INVESTMENT IN TNF PHARMACEUTICA

INVESTMENT IN TNF PHARMACEUTICALS, INC.	6 Months Ended
INVESTMENT IN TNF PHARMACEUTICALS, INC.	Oct. 31, 2024
Investments, Debt and Equity Securities [Abstract]
INVESTMENT IN TNF PHARMACEUTICALS, INC.	NOTE 13 – INVESTMENT IN TNF PHARMACEUTICALS, INC. On May 20, 2024, the Company entered into a Securities Purchase Agreement (the “SPA”) with a public company operating in the medical industry, MyMD Pharmaceuticals, Inc. which subsequently changed its name to TNF Pharmaceuticals, Inc., (“TNF”). Pursuant to the SPA, the Company purchased (i) 7,000 3,854,626 3,854,626 7,000,000 Pursuant to the SPA, the Company has the right to participate in future sales of TNF’s equity and equity-linked securities until the second anniversary of the Closing or the date on which no TNF Preferred Shares remain outstanding, whichever is earlier. Additionally, the Company has the right to nominate one individual to serve on TNF’s board of directors until PharmaCyte no longer beneficially owns at least 20% of TNF’s common stock on an as-converted basis. The Company’s Interim Chief Executive Officer serves on the board of directors of TNF. The Company has determined that TNF is a VIE, since TNF does not have sufficient equity at risk to finance its own operations without additional subordinated financial support. However, the Company has determined that it is not the primary beneficiary of TNF. Furthermore, TNF’s Series G Preferred Stock is not considered in substance common stock, and as such, equity method accounting does not apply. The Company recorded its investment in TNF Series G Preferred Stock at its fair value of approximately $ 17,410,000 The Warrants were determined to meet the definition of a derivative and were required to be recorded at fair value in accordance with ASC 815. Subsequent changes in the fair value of the Warrants are recognized in earnings, at each reporting date. The approximately $ 10,986,000 During the three and six months ending October 31, 2024, the Company recognized a loss for the change in fair value of the Investment – TNF of approximately $ 4,265,000 3,541,000 18,799,000 Below is a summary of activity for the Preferred Stock as of October 31, 2024: Summary of investment stock and warrants Balance of Preferred Stock as of April 30, 2024 $ – Purchased 17,410,050 Change in fair value 1,388,950 Balance of Warrant assets as of October 31, 2024 $ 18,799,000 Below is a summary of activity for the Preferred Stock Warrants as of October 31, 2024: Balance of Warrant assets as of April 30, 2024 $ – Purchased 10,985,684 Change in fair value (4,929,684 ) Balance of Warrant assets as of October 31, 2024 $ 6,056,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Oct. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 – SUBSEQUENT EVENTS Stock Repurchase From November 1, 2024 to December 9, 2024, the Company repurchased 66,125 shares of common stock through the stock repurchase program for $121,015, including commissions and accrued excise taxes. On November 21, 2024, the Company received 315,790 shares of Femasys common stock in settlement on interest income on the Femasys Notes of $300,000.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Oct. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of October 31, 2024 and for the three and six months then ended. The results of operations for the three and six months ended October 31, 2024 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of April 30, 2024 and for the year then ended which are included in the Company’s Annual Report on Form 10- K, filed with the SEC on August 13, 2024.
Liquidity Uncertainties	Liquidity Uncertainties As of October 31, 2024, the Company had approximately $ 20.8 50.2 The Company may need to raise additional capital in order to initiate and pursue potential additional projects, including the continuing development beyond the ongoing pancreatic cancer research. Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders, and debt financing, if available, may have restrictive covenants. If the Company is able to find funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its product candidates that the Company would otherwise seek to develop on its own, on terms that may not be favorable to the Company. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on the business, financial condition and results of operations.
Basic and Diluted Income (Loss) Per Share	Basic and Diluted Income (Loss) Per Share Basic earnings per share excludes dilution for common stock equivalents and is computed by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted EPS is calculated based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period. Potentially dilutive securities consist of common stock options, warrants, and convertible preferred securities. The dilutive effect of stock options and warrants is reflected in diluted EPS by application of the treasury stock method. The dilutive effect of convertible preferred securities is reflected in the diluted EPS by application of the “if-converted” method. The “if-converted” method is only assumed in periods where such application would be dilutive. Basic and diluted net income (loss) per share is determined by dividing income (loss) by the weighted average ordinary shares outstanding during the period. For periods presented with a net loss, the shares underlying the ordinary share options, warrants and preferred stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per share is the same for periods with a net loss.
Investment in TNF Pharmaceuticals, Inc.	Investment in TNF Pharmaceuticals, Inc. In accordance with ASC 810, Consolidation If an entity is determined to be a VIE, the Company evaluates whether it is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. PharmaCyte consolidates a VIE if it has both power and benefits that is, PharmaCyte (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). PharmaCyte consolidates VIEs whenever it is determined that PharmaCyte is the primary beneficiary. The Company applies ASC 321 Investments—Equity Securities
New Accounting Pronouncements Effective in Future Periods	New Accounting Pronouncements Effective in Future Periods In November 2023, FASB issued ASU 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities with a single reportable segment to provide all the disclosures required by this standard and all existing segment disclosures in Topic 280 on an interim and annual basis, including new requirements to disclose significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within the reported measure(s) of a segment's profit or loss, the amount and composition of any other segment items, the title and position of the CODM, and how the CODM uses the reported measure(s) of a segment's profit or loss to assess performance and decide how to allocate resources. The guidance is effective for our annual period beginning May 1, 2025, and interim periods, thereafter, applied retrospectively with early adoption permitted. The Company is evaluating the impact of adoption of this standard on its financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to provide greater disaggregation within their annual rate reconciliation, including new requirements to present reconciling items on a gross basis in specified categories, disclose both percentages and dollar amounts, and disaggregate individual reconciling items by jurisdiction and nature when the effect of the items meet a quantitative threshold. The guidance also requires disaggregating the annual disclosure of income taxes paid, net of refunds received, by federal (national), state, and foreign taxes, with separate presentation of individual jurisdictions that meet a quantitative threshold. The guidance is effective for the Company's annual periods beginning May 1, 2025 on a prospective basis, with a retrospective option, and early adoption is permitted. The Company is evaluating the impact of adoption of this standard on its financial statements and disclosures.

INVESTMENT IN FEMASYS SECURIT_2

INVESTMENT IN FEMASYS SECURITIES (Tables)	6 Months Ended
INVESTMENT IN FEMASYS SECURITIES (Tables)	Oct. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of activity for the notes and warrants	Schedule of activity for the notes and warrants Balance of Notes as of May 1, 2024 $ 2,755,000 Purchased – Change in fair value 680,000 Balance of Notes as of October 31, 2024 $ 3,435,000 Balance of Warrants as of May 1, 2024 $ 5,152,000 Purchased – Change in fair value (1,234,000 ) Balance of Warrants as of October 31, 2024 $ 3,918,000

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	6 Months Ended
ACCRUED EXPENSES (Tables)	Oct. 31, 2024
Payables and Accruals [Abstract]
Schedule of accrued expenses	Schedule of accrued expenses October 31, 2024 April 30, 2024 Payroll related costs $ 185,846 $ 167,817 Director fees 67,500 135,000 R&D costs 92,310 92,310 Excise tax on stock repurchases 361,529 340,072 Total $ 707,185 $ 735,199

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	6 Months Ended
STOCK OPTIONS AND WARRANTS (Tables)	Oct. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of stock option activity and related information	Schedule of stock option activity and related information Options Number of Options Weighted Average Exercise Price per Share Outstanding, April 30, 2024 925,164 $ 2.97 Issued – – Expired (1,466 ) 55.30 Outstanding, October 31, 2024 923,698 $ 2.89 Exercisable, October 31, 2024 644,161 $ 3.21 Vested and expected to vest 923,698 $ 2.89
Schedule of unvested stock option activity	Schedule of unvested stock option activity Options Weighted Unvested, April 30, 2024 279,536 1.70 Granted – – Vested – – Forfeited – – Unvested, October 31, 2024 279,536 $ 1.70
Schedule of warrant activity and related information	Schedule of warrant activity and related information Warrants Weighted Per Share Outstanding, April 30, 2024 18,570,847 $ 4.54 Issued – – Exercised – – Expired – – Outstanding, October 31, 2024 18,570,847 4.54 Exercisable, October 31, 2024 18,570,847 $ 4.54

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
EARNINGS PER SHARE (Tables)	Oct. 31, 2024
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings (loss) per share	Schedule of basic and diluted earnings (loss) per share Three Months Ended October 31, 2024 2023 Earnings per share Net income (loss) $ (1,469,560 ) $ 2,789,896 Less: Accretion of discounts to redemption of Series B convertible preferred stock (443,958 ) (586,886 ) Less: Series B convertible preferred stock dividends (1,045,357 ) (4,461,097 ) Less: Allocation of undistributed income to Series B convertible preferred stock – – Net loss attributable to common stockholders $ (2,958,875 ) $ (2,258,087 ) Weighted average shares outstanding used in basic and diluted earnings per share 7,637,034 8,765,134 Net loss per share basic and diluted $ (0.39 ) $ (0.26 ) Six Months Ended October 31, 2024 2023 Earnings per share Net income (loss) $ 21,951,795 $ (393,401 ) Less: Accretion of discounts to redemption of Series B convertible preferred stock (3,193,404 ) (7,733,130 ) Less: Series B convertible preferred stock dividends (1,129,759 ) (906,735 ) Less: Allocation of undistributed income to Series B convertible preferred stock (3,409,913 ) – Undistributed income (loss) available to common stockholders $ 14,218,719 $ (9,033,266 ) Weighted average shares outstanding used in basic earnings per share 7,751,708 10,683,514 Net income (loss) per share basic and diluted $ 1.83 $ (0.85 )
Schedule of potentially dilutive securities	Schedule of potentially dilutive securities Three and Six Months Ended 2024 2023 Excluded options 923,696 279,802 Excluded warrants 18,570,847 18,570,847 Total excluded options and warrants 19,494,543 18,850,649

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Oct. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of fair value of financial liabilities	Schedule of fair value of financial liabilities Description Level October 31, 2024 April 30, 2024 Liabilities: Warrant liability 3 $ 6,871,000 $ 10,784,000 Bifurcated embedded derivative 3 $ – $ 2,184,000
Schedule of change in the fair value of the warrant liability	Schedule of change in the fair value of the warrant liability Three Months Ended October 31, 2024 Balance on July 31, 2024 $ 8,700,000 Issuance of warrants – Change in fair value of warrant liability (1,829,000 ) Balance on October 31, 2024 $ 6,871,000 Six Months Ended October 31, 2024 Balance on April 30, 2024 $ 10,784,000 Issuance of warrants – Change in fair value of warrant liability (3,913,000 ) Balance on October 31, 2024 $ 6,871,000
Schedule of embedded derivative liability	Schedule of embedded derivative liability Three Months Ended October 31, 2024 Balance on July 31, 2024 $ 980,000 Issuance of convertible preferred stock with bifurcated embedded derivative liability – Change in fair value of bifurcated embedded derivative (980,000 ) Balance on October 31, 2024 $ – Six Months Ended October 31, 2024 Balance on April 30, 2024 $ 2,184,000 Issuance of convertible preferred stock with bifurcated embedded derivative liability – Change in fair value of bifurcated embedded derivative (2,184,000 ) Balance on October 31, 2024 $ –
Schedule of fair values of financial instruments by class	Schedule of fair values of financial instruments by class Level October 31, 2024 April 30, 2024 Financial Assets Convertible note receivable – investment in debt security 3 $ 3,435,000 $ 2,755,000 Warrant asset – Femasys 3 $ 3,918,000 $ 5,152,000 Investment in preferred stock - TNF 3 $ 18,799,000 $ – Warrant asset – TNF 3 $ 6,056,000 $ –

INVESTMENT IN TNF PHARMACEUTI_2

INVESTMENT IN TNF PHARMACEUTICALS, INC. (Tables)	6 Months Ended
INVESTMENT IN TNF PHARMACEUTICALS, INC. (Tables)	Oct. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Summary of investment stock and warrants	Summary of investment stock and warrants Balance of Preferred Stock as of April 30, 2024 $ – Purchased 17,410,050 Change in fair value 1,388,950 Balance of Warrant assets as of October 31, 2024 $ 18,799,000 Below is a summary of activity for the Preferred Stock Warrants as of October 31, 2024: Balance of Warrant assets as of April 30, 2024 $ – Purchased 10,985,684 Change in fair value (4,929,684 ) Balance of Warrant assets as of October 31, 2024 $ 6,056,000

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Oct. 31, 2024	Apr. 30, 2024
Accounting Policies [Abstract]
Cash and cash equivalents	$ 20,840,056	$ 50,179,968

INVESTMENT IN FEMASYS SECURIT_3

INVESTMENT IN FEMASYS SECURITIES (Details - Note and warrants)	6 Months Ended
	Oct. 31, 2024 USD ($)
Femasys Notes [Member]
Schedule of Investments [Line Items]
Investment, beginning balance	$ 2,755,000
Purchased	0
Change in fair value	680,000
Investment, ending balance	3,435,000
Femasys Warrants [Member]
Schedule of Investments [Line Items]
Investment, beginning balance	5,152,000
Purchased	0
Change in fair value	(1,234,000)
Investment, ending balance	$ 3,918,000

INVESTMENT IN FEMASYS SECURIT_4

INVESTMENT IN FEMASYS SECURITIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023	Nov. 14, 2023
Offsetting Assets [Line Items]
Change in fair value of convertible note receivable	$ 435,000	$ 0	$ 680,000	$ 0
Change in fair value of warrant asset loss - Femasys	$ 276,000	$ 0	$ (1,234,000)	$ 0
Femasys Purchase Agreement [Member] \| Femasys Note [Member]
Offsetting Assets [Line Items]
Investment fair value					$ 1,666,000
Femasys Purchase Agreement [Member] \| Femasys Warrants [Member]
Offsetting Assets [Line Items]
Investment fair value					3,334,000
Femasys Purchase Agreement [Member]
Offsetting Assets [Line Items]
Note receivable face amount					$ 5,000,000
Receivable conversion price					$ 1.18
Femasys Purchase Agreement [Member] \| Femasys Warrants [Member]
Offsetting Assets [Line Items]
Investment shares owned					4,237,288

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)	Oct. 31, 2024	Apr. 30, 2024
Accrued liabilities	$ 707,185	$ 735,199
Payroll related costs [Member]
Accrued liabilities	185,846	167,817
Director fees [Member]
Accrued liabilities	67,500	135,000
R&D costs [Member]
Accrued liabilities	92,310	92,310
Excise tax on stock repurchases [Member]
Accrued liabilities	$ 361,529	$ 340,072

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details - Option activity) - Equity Option [Member]	6 Months Ended
	Oct. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, beginning \| shares	925,164
Weighted average exercise price per share, beginning \| $ / shares	$ 2.97
Number of options, issued \| shares	0
Weighted average exercise price per share, granted \| $ / shares	$ 0
Number of options, expired \| shares	(1,466)
Weighted average exercise price per share, expired \| $ / shares	$ 55.30
Number of options outstanding, ending \| shares	923,698
Weighted average exercise price per share, ending \| $ / shares	$ 2.89
Number of options exercisable \| shares	644,161
Weighted average exercise price per share, exercisable \| $ / shares	$ 3.21
Number of options vested and expected to vest \| shares	923,698
Weighted average exercise price per share, vested and expected to vest \| $ / shares	$ 2.89

STOCK OPTIONS AND WARRANTS (D_2

STOCK OPTIONS AND WARRANTS (Details - Unvested option activity) - Unvested Stock Options [Member]	6 Months Ended
	Oct. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares unvested outsatnding, beginning \| shares	279,536
Weighted average grant date fair value, beginning \| $ / shares	$ 1.70
Granted, options \| shares	0
Weighted average grant date fair value, granted \| $ / shares	$ 0
Vested, options \| shares	0
Weighted average grant date fair value, vested \| $ / shares	$ 0
Forfeited, options \| shares	0
Weighted average grant date fair value, forfeited \| $ / shares	$ 0
Number of shares unvested outsatnding, ending \| shares	279,536
Weighted average grant date fair value, ending \| $ / shares	$ 1.70

STOCK OPTIONS AND WARRANTS (D_3

STOCK OPTIONS AND WARRANTS (Details - Warrant activity) - Warrant [Member]	6 Months Ended
	Oct. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants outstanding, beginning balance \| shares	18,570,847
Weighted average exercise price warrants outstanding, beginning balance \| $ / shares	$ 4.54
Warrants issued \| shares	0
Weighted average exercise price warrants issued \| $ / shares	$ 0
Warrants exercised \| shares	0
Weighted average exercise price warrants Exercised \| $ / shares	$ 0
Warrants expired \| shares	0
Weighted average exercise price warrants Expired \| $ / shares	$ 0
Warrants outstanding, ending balance \| shares	18,570,847
Weighted average exercise price warrants outstanding, ending balance \| $ / shares	$ 4.54
Warrants exercisable \| shares	18,570,847
Weighted average exercise price warrants exercisable \| $ / shares	$ 4.54

STOCK OPTIONS AND WARRANTS (D_4

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	May 10, 2023	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023	Apr. 30, 2024	Dec. 28, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation				$ 341,832	$ 0
Change in fair value of warrant liability		$ 1,829,000	$ 4,075,000	$ 3,913,000	$ 2,623,000
Private Placement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants issued, common shares available for purchase	8,750,000
Purchase of common stock price per share	$ 4
Fair value of warrants issued	$ 14,127,000
Transaction costs for issuance of warrants	$ 913,640
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options outstanding		923,698		923,698		925,164
Number of shares granted				0
Aggregate intrinsic value		$ 0		$ 0
Equity Option [Member] \| Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares granted				0	0
Stock-based compensation		119,155	$ 0	$ 341,833	$ 0
Employee service unrecognized compensation expense		$ 132,859		$ 132,859
Equity Option [Member] \| Non Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares granted				0	0
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Purchase of common stock price per share		$ 4.54		$ 4.54		$ 4.54
Fair value of warrants		$ 6,871,000		$ 6,871,000
Equity Plan 2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available							2,750,000

OTHER RELATED PARTY TRANSACTI_2

OTHER RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
SG Austria [Member]
Related Party Transaction [Line Items]
Purchases from related parties	$ 0	$ 0	$ 0	$ 0
Vin-de-Bona [Member]
Related Party Transaction [Line Items]
Consulting fees	$ 2,670	$ 2,590	$ 5,280	$ 2,700
SG Australia [Member]
Related Party Transaction [Line Items]
Equity interest owned	13.90%		13.90%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Rent expenses	$ 7,071	$ 6,631	$ 14,281	$ 15,598

EARNINGS PER SHARE (Details - P

EARNINGS PER SHARE (Details - Per share calculation) - USD ($)	3 Months Ended				6 Months Ended
	Oct. 31, 2024	Jul. 31, 2024	Oct. 31, 2023	Jul. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Earnings Per Share [Abstract]
Net income (loss)	$ (1,469,560)	$ 23,421,355	$ 2,789,896	$ (3,183,297)	$ 21,951,795	$ (393,401)
Less: Accretion of discounts to redemption of Series B convertible preferred stock	(443,958)		(586,886)		(3,193,404)	(7,733,130)
Less: Series B convertible preferred stock dividends	(1,045,357)		(4,461,097)		(1,129,759)	(906,735)
Less: Allocation of undistributed income to Series B convertible preferred stock	0		0		$ (3,409,913)	$ 0
Net loss attributable to common stockholders	$ (2,958,875)		$ (2,258,087)
Weighted average shares outstanding used in basic earnings per share	7,637,034		8,765,134		7,751,708	10,683,514
Weighted average shares outstanding used in diluted earnings per share	7,637,034		8,765,134		7,751,708	10,683,514
Net income (loss) per share basic	$ (0.39)		$ (0.26)		$ 1.83	$ (0.85)
Net income (loss) per share basic	$ (0.39)		$ (0.26)		$ 1.83	$ (0.85)
Undistributed income (loss) available to common stockholders					$ 14,218,719	$ (9,033,266)

EARNINGS PER SHARE (Details - D

EARNINGS PER SHARE (Details - Diluted shares) - shares	3 Months Ended		6 Months Ended
EARNINGS PER SHARE (Details - Diluted shares) - shares	Oct. 31, 2024	Oct. 31, 2023	Oct. 31, 2024	Oct. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	19,494,543	18,850,649	19,494,543	18,850,649
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	923,696	279,802	923,696	279,802
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	18,570,847	18,570,847	18,570,847	18,570,847

PREFERRED STOCK (Details Narrat

PREFERRED STOCK (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
PREFERRED STOCK (Details Narrative) - USD ($)	Oct. 31, 2024	Oct. 31, 2024	Apr. 30, 2024
Class of Stock [Line Items]
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Change in fair value of the derivative liability	$ 980,000	$ 2,184,000
Fair value of embedded derivative	0	0
Payment of Preferred redemption amounts	9,336,833	18,766,416
Accretion expense	1,045,357	3,193,404
Deemed dividend	528,500	1,062,250
Accrued dividends	3,720,458	3,720,458	$ 6,296,696
Stated Value Of Preferred Shares [Member]
Class of Stock [Line Items]
Accrued dividends	2,979,167	2,979,167
Dividends Payable [Member]
Class of Stock [Line Items]
Accrued dividends	530,698	530,698
Series B Cash Premium [Member]
Class of Stock [Line Items]
Accrued dividends	$ 210,593	$ 210,593
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock shares designated	35,000	35,000
Temporary equity, shares issued	0	0	14,646
Temporary equity, shares outstanding	0	0	14,646
Share redemption value	$ 0	$ 0	$ 11,867,016
Preferred Shares [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding	0	0
Payment of Preferred redemption amounts	$ 8,750,000	$ 17,500,000
Accrued Dividends [Member]
Class of Stock [Line Items]
Payment of Preferred redemption amounts	58,333	204,166
Cash Premium [Member]
Class of Stock [Line Items]
Payment of Preferred redemption amounts	$ 528,500	$ 1,062,250

TREASURY STOCK (Details Narrati

TREASURY STOCK (Details Narrative) - USD ($)		3 Months Ended			6 Months Ended
TREASURY STOCK (Details Narrative) - USD ($)	Jun. 09, 2023	Oct. 31, 2024	Jul. 31, 2024	Jul. 31, 2023	Oct. 31, 2024	Apr. 30, 2024	May 31, 2022
Class of Stock [Line Items]
Number of shares repurchased, value		$ 1,417,565	$ 749,600	$ 26,721,897
Treasury stock, common shares		14,637,836			14,637,836	13,634,454
Treasury stock, value		$ 44,207,381			$ 44,207,381	$ 42,040,216
May 2022 Repurchase Program [Member]
Class of Stock [Line Items]
Stock repurchase maximum amount authorized							$ 10,000,000
Stock repurchase program, remaining amount		$ 2,514,516			$ 2,514,516
May 2022 Repurchase Program [Member] \| Treasury Stock, Common [Member]
Class of Stock [Line Items]
Number of shares repurchased		683,036			1,003,382
Number of shares repurchased, value		$ 1,417,565			$ 2,167,165
Number of shares repurchased					6,551,957
Stock repurchased, value					$ 17,485,484
May 2023 Tender Offer [Member]
Class of Stock [Line Items]
Stock repurchased, value	$ 26,721,897
Stock repurchase, shares authorized	8,085,879

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details - Fair value) - Fair Value, Recurring [Member] - USD ($)	Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial liability	$ 6,871,000	$ 8,700,000	$ 10,784,000
Fair Value, Inputs, Level 3 [Member] \| Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial liability	6,871,000		10,784,000
Fair Value, Inputs, Level 3 [Member] \| Bifurcated Embedded Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial liability	$ 0		$ 2,184,000

FAIR VALUE MEASUREMENTS (Deta_2

FAIR VALUE MEASUREMENTS (Details - Changes in fair value) - Fair Value, Recurring [Member] - USD ($)	3 Months Ended	6 Months Ended
	Oct. 31, 2024	Oct. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance on April 30, 2024	$ 8,700,000	$ 10,784,000
Issuance of warrants	0	0
Change in fair value of warrant liability	(1,829,000)	(3,913,000)
Balance on October 31, 2024	$ 6,871,000	$ 6,871,000

FAIR VALUE MEASUREMENTS (Deta_3

FAIR VALUE MEASUREMENTS (Details - Embedded derivative fair value) - Fair Value, Recurring [Member] - USD ($)	3 Months Ended	6 Months Ended
	Oct. 31, 2024	Oct. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance on April 30, 2024	$ 980,000	$ 2,184,000
Issuance of convertible preferred stock with bifurcated embedded derivative liability	0	0
Change in fair value of bifurcated embedded derivative	(980,000)	(2,184,000)
Balance on October 31, 2024	$ 0	$ 0

FAIR VALUE MEASUREMENTS (Deta_4

FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments) - Fair Value, Inputs, Level 3 [Member] - USD ($)	Oct. 31, 2024	Apr. 30, 2024
Convertible Note Receivable [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of financial assets	$ 3,435,000	$ 2,755,000
Warrant asset Femasys [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of financial assets	3,918,000	5,152,000
Investment in preferred stock - TNF [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of financial assets	18,799,000	0
Warrant asset TNF [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of financial assets	$ 6,056,000	$ 0

INVESTMENT IN TNF PHARMACEUTI_3

INVESTMENT IN TNF PHARMACEUTICALS, INC. (Details - Preferred stock)	6 Months Ended
	Oct. 31, 2024 USD ($)
MyMD Preferred Stock [Member]
Marketable Securities [Line Items]
Fair value of financial assets at beginning	$ 0
Fair value of investment, purchases	17,410,050
Change in fair value of investment	1,388,950
Fair value of financial assets at ending	18,799,000
MyMD Preferred Stock Warrants [Member]
Marketable Securities [Line Items]
Fair value of financial assets at beginning	0
Fair value of investment, purchases	10,985,684
Change in fair value of investment	(4,929,684)
Fair value of financial assets at ending	$ 6,056,000

INVESTMENT IN TNF PHARMACEUTI_4

INVESTMENT IN TNF PHARMACEUTICALS, INC. (Details Narrative) - USD ($)		3 Months Ended	6 Months Ended
	May 20, 2024	Oct. 31, 2024	Oct. 31, 2024	Oct. 31, 2023	May 23, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for investment			$ 7,000,000	$ 0
Change in fair value of investment Tnf - loss		$ 4,265,000	3,541,000
TNF Series G Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment owned fair value					$ 17,410,000
TNF Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment owned fair value					$ 10,986,000
TNF [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment owned fair value		$ 18,799,000	$ 18,799,000
Securities Purchase Agreement [Member] \| TNF Pharmaceuticals Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for investment	$ 7,000,000
Securities Purchase Agreement [Member] \| TNF Pharmaceuticals Inc [Member] \| TNF Series G Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment shares owned	7,000
Number of common shares issuable upon conversion of preferred stock	3,854,626
Securities Purchase Agreement [Member] \| TNF Pharmaceuticals Inc [Member] \| TNF Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment shares owned	3,854,626